(Total Views: 788)
Posted On: 09/04/2020 2:07:41 AM
Post# of 153903
The problem with using either CCR5 delta32 double allele deletion or CCR5 null mice as a comparison is that leronlimab doesn't act like either. You need to do deep,deep digging to figure out what effect leronlimab would have.
In the case of CCR5 delta32 deletion, evolution would cause other receptors to take up the slack in immune response. For CCR5 null mice you'd have a shutdown of a large part of the immune response, it's a bit similar to maraviroc. Leronlimab's partial blockade was lucky happenstance when it came to other indications.
What chemokines besides RANTES (CCL5) does leronlimab block? Much to my consternation since basic research has never been done we don't know. Dr. Patterson's continued research could have clued us in but not anymore. I've tried to figure it out by looking at molecular diagrams but with no luck.
In the case of CCR5 delta32 deletion, evolution would cause other receptors to take up the slack in immune response. For CCR5 null mice you'd have a shutdown of a large part of the immune response, it's a bit similar to maraviroc. Leronlimab's partial blockade was lucky happenstance when it came to other indications.
What chemokines besides RANTES (CCL5) does leronlimab block? Much to my consternation since basic research has never been done we don't know. Dr. Patterson's continued research could have clued us in but not anymore. I've tried to figure it out by looking at molecular diagrams but with no luck.
(3)
(0)
